title: Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis.
abstract: OBJECTIVE
  To report the results of repeated bilateral sequential photodynamic therapy (PDT) with verteporfin for sub-retinal neovascularization associated with parafoveal telengiectasia.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Three patients (minimum of 6-month follow-up) were analyzed after bilateral sequential PDT for parafoveal telengiectasia-associated sub-retinal neovascularization.
  
  
  RESULTS
  Mean age was 53.3 +/- 2.1 years. Mean and median follow-up duration were 12.3 and 10 months, respectively. Mean initial Early Treatment of Diabetic Retinopathy Study chart letter acuity was 30.6 in right eyes and 19 in left eyes, and at month 6, it was 30.6 in right eyes and 22.3 in left eyes. All patients received bilateral treatment three times; one eye received a fourth treatment. The greatest linear diameter was between 2310 and 5400 microm.
  
  
  CONCLUSIONS
  PDT is a viable treatment for sub-retinal neovascularization associated with parafoveal telengiectasia. Bilateral sequential treatment is a convenient way to treat bilateral disease.
authors.affiliation: Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Eye Institute, L.V. Prasad Marg, Andhra Pradesh, India. nazimul@lvpei.org
authors.forename: Nazimul
authors.initials: N
authors.lastname: Hussain
authors.forename: Taraprasad
authors.initials: T
authors.lastname: Das
authors.forename: Kallukuri
authors.initials: K
authors.lastname: Sumasri
authors.forename: L S Mohan
authors.initials: LS
authors.lastname: Ram
mesh_terms: D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D019233:Retreatment; D013684:Telangiectasis / Q000175:diagnosis / Q000188:drug therapy*; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin